Mario Negri Institute for Pharmacological Research
PharmaMilan, Italy, Italy · Est. 1963
Mario Negri Institute for Pharmacological Research is an independent, non-profit research organization focused on drug discovery and development in therapeutic areas including oncology, cardiovascular disease, and neurology.
1
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
7
Indications↗
Distinct diseases across all programs
88
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
1 drugs in development
Approved1
Preclinical1
By Therapeutic Area
top 3
Neurology
133%
Musculoskeletal
133%
Infectious Disease
133%
R&D Momentum
52/100
Pipeline Velocity
19/100
Trial Completion Rate
68/100
Pipeline Concentration
33/100
Pipeline Freshness
68/100
Strategic Signals
- ↗Active in Neurology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Jul 14, 2026
Completed
Rescue Therapy With the Human Anti-CD38 Antibody MOR202 (Felzartamab) in Patients With Membranous Nephropathy Who Failed Anti-CD20 Target Therapy
Jul 7, 2026
Recruiting
Study of Pathological and Regenerative Molecular and Cellular Processes Triggered After Traumatic Brain Injury: Analysis of Biopsy Specimens
Earlier
Jun 26, 2026TrialA Phase IV Trial to Confirm the Efficacy of Olaparib in Combination With Bevacizumab as Frontline Treatment of HRD Positive Ovarian Tumors
Jun 24, 2026TrialDeciphering the Role of Thyroid Hormones in Severe Non-ADPKD Chronic Kidney Disease
Apr 30, 2026TrialPragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib
Feb 1, 2026TrialObinutuzumab in Adult Rituximab-Dependent Nephrotic Syndrome
Aug 7, 2025TrialPhase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen
Jul 8, 2025TrialPatiromer and Diet/hrQoL in Chronic Dialysis
Details
Company Info
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Therapeutic Focus
OncologyCardiovascularNeurology
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Infectious Disease
Infectious Disease
Musculoskeletal
Osteoarthritis
Acetyl-L-carnitinePreclinical
Neurology
Ataxia
Acetyl-L-carnitinePreclinical
Encephalopathy
Acetyl-L-carnitinePreclinical
Migraine
Acetyl-L-carnitineApproved
Peripheral Neuropathy
Acetyl-L-carnitinePreclinical
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)